PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33842334-7	2021	Application of AhR inhibitor DMF could efficiently suppress distant metastasis of renal cancer cells, and improve anticancer effects of sorafenib (Sor)/sunitinib (Sun), which described a promising therapeutic strategy for clinical renal cancer.	Sorafenib	136-145	aryl hydrocarbon receptor	Homo sapiens	15-18	
33842334-7	2021	Application of AhR inhibitor DMF could efficiently suppress distant metastasis of renal cancer cells, and improve anticancer effects of sorafenib (Sor)/sunitinib (Sun), which described a promising therapeutic strategy for clinical renal cancer.	Sorafenib	147-150	aryl hydrocarbon receptor	Homo sapiens	15-18	
35124147-0	2022	Sorafenib is an antagonist of the aryl hydrocarbon receptor.	Sorafenib	0-9	aryl hydrocarbon receptor	Homo sapiens	34-59	
35124147-11	2022	Sorafenib"s antagonistic action on AhR was comparable to that of the known AhR antagonist CH-223191 in human liver and ovarian cell lines.	Sorafenib	0-9	aryl hydrocarbon receptor	Homo sapiens	35-38	
35124147-12	2022	In summary, we demonstrate that sorafenib is a potent AhR antagonist and likely endocrine disruptor of the AhR.	Sorafenib	32-41	aryl hydrocarbon receptor	Homo sapiens	54-57	
35124147-12	2022	In summary, we demonstrate that sorafenib is a potent AhR antagonist and likely endocrine disruptor of the AhR.	Sorafenib	32-41	aryl hydrocarbon receptor	Homo sapiens	107-110	
35124147-13	2022	Moreover, sorafenib offers potential benefit for diseases treatable through AhR suppression strategies.	Sorafenib	10-19	aryl hydrocarbon receptor	Homo sapiens	76-79	
35124147-14	2022	Further investigation is warranted into sorafenib"s AhR antagonistic behavior.	Sorafenib	40-49	aryl hydrocarbon receptor	Homo sapiens	52-55